Financial Ratios Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi
Equities
ONCSM
TREONCO00026
Advanced Medical Equipment & Technology
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
175.70 TRY | -9.99% | -3.99% | +17.45% |
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Profitability | |||
Return on Assets | - | 13.45 | -10.84 |
Return on Total Capital | - | 18.92 | -13.77 |
Return On Equity % | - | 27.9 | -35.02 |
Return on Common Equity | - | 27.9 | -35.02 |
Margin Analysis | |||
Gross Profit Margin % | 69.02 | 43.62 | 14.88 |
SG&A Margin | 12.29 | 20.16 | 33.62 |
EBITDA Margin % | 60.23 | 29.8 | -11.07 |
EBITA Margin % | 54.98 | 22.74 | -24.8 |
EBIT Margin % | 54.98 | 22.74 | -24.8 |
Income From Continuing Operations Margin % | 56.05 | 18.14 | -33.18 |
Net Income Margin % | 56.05 | 18.14 | -33.18 |
Net Avail. For Common Margin % | 56.05 | 18.14 | -33.18 |
Normalized Net Income Margin | 39.71 | 14.88 | -24.78 |
Levered Free Cash Flow Margin | - | 2.13 | -16.62 |
Unlevered Free Cash Flow Margin | - | 2.62 | -14.06 |
Asset Turnover | |||
Asset Turnover | - | 0.95 | 0.7 |
Fixed Assets Turnover | - | 3.42 | 1.89 |
Receivables Turnover (Average Receivables) | - | 3.74 | 3.93 |
Inventory Turnover (Average Inventory) | - | 1.7 | 2.34 |
Short Term Liquidity | |||
Current Ratio | 1.94 | 2 | 2.16 |
Quick Ratio | 0.9 | 0.91 | 1.25 |
Operating Cash Flow to Current Liabilities | 1.17 | 0.36 | -0.42 |
Days Sales Outstanding (Average Receivables) | - | 97.58 | 92.78 |
Days Outstanding Inventory (Average Inventory) | - | 214.46 | 155.79 |
Average Days Payable Outstanding | - | 52.95 | 41.2 |
Cash Conversion Cycle (Average Days) | - | 259.09 | 207.37 |
Long Term Solvency | |||
Total Debt/Equity | 18.17 | 13.54 | 26.92 |
Total Debt / Total Capital | 15.38 | 11.93 | 21.21 |
LT Debt/Equity | 5.83 | 2.11 | 0.58 |
Long-Term Debt / Total Capital | 4.94 | 1.86 | 0.46 |
Total Liabilities / Total Assets | 39.18 | 37.89 | 31.51 |
EBIT / Interest Expense | 27 | 28.6 | -6.04 |
EBITDA / Interest Expense | 30.07 | 38.54 | -2.33 |
(EBITDA - Capex) / Interest Expense | 25.87 | 26.06 | -5.14 |
Total Debt / EBITDA | 0.18 | 0.33 | -2.72 |
Net Debt / EBITDA | 0.11 | 0.06 | -0.17 |
Total Debt / (EBITDA - Capex) | 0.21 | 0.48 | -1.23 |
Net Debt / (EBITDA - Capex) | 0.13 | 0.08 | -0.08 |
Growth Over Prior Year | |||
Total Revenues, 1 Yr. Growth % | - | 9.8 | -17.9 |
Gross Profit, 1 Yr. Growth % | - | -30.61 | -64.46 |
EBITDA, 1 Yr. Growth % | - | -45.68 | -140.58 |
EBITA, 1 Yr. Growth % | - | -54.59 | -280.65 |
EBIT, 1 Yr. Growth % | - | -54.59 | -280.65 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | -64.46 | 284.37 |
Net Income, 1 Yr. Growth % | - | -64.46 | 284.37 |
Normalized Net Income, 1 Yr. Growth % | - | -58.85 | -29.45K |
Diluted EPS Before Extra, 1 Yr. Growth % | - | - | 96.85 |
Accounts Receivable, 1 Yr. Growth % | - | 21.27 | -19.81 |
Inventory, 1 Yr. Growth % | - | 35.88 | -15.55 |
Net Property, Plant and Equip., 1 Yr. Growth % | - | 8.77 | -13.72 |
Total Assets, 1 Yr. Growth % | - | 29.2 | -3.22 |
Tangible Book Value, 1 Yr. Growth % | - | 33.78 | 2.79 |
Common Equity, 1 Yr. Growth % | - | 31.93 | 3.4 |
Cash From Operations, 1 Yr. Growth % | - | -59.32 | -172.32 |
Capital Expenditures, 1 Yr. Growth % | - | 27.23 | 6.54 |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | 58.62 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | 41.26 |
Compound Annual Growth Rate Over Two Years | |||
Total Revenues, 2 Yr. CAGR % | - | - | 37.08 |
Gross Profit, 2 Yr. CAGR % | - | - | -36.35 |
EBITDA, 2 Yr. CAGR % | - | - | -41.23 |
EBITA, 2 Yr. CAGR % | - | - | -7.94 |
EBIT, 2 Yr. CAGR % | - | - | -7.94 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 5.48 |
Net Income, 2 Yr. CAGR % | - | - | 5.48 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 8.28 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | -89.46 |
Accounts Receivable, 2 Yr. CAGR % | - | - | 26.58 |
Inventory, 2 Yr. CAGR % | - | - | 42.37 |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 73.36 |
Total Assets, 2 Yr. CAGR % | - | - | 61.6 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 71.73 |
Common Equity, 2 Yr. CAGR % | - | - | 71.48 |
Cash From Operations, 2 Yr. CAGR % | - | - | -14.17 |
Capital Expenditures, 2 Yr. CAGR % | - | - | 59.01 |
MarketScreener is also available in this country: United States.
Switch edition